Anders Gülfe

1.5k total citations
21 papers, 1.1k citations indexed

About

Anders Gülfe is a scholar working on Rheumatology, Economics and Econometrics and Surgery. According to data from OpenAlex, Anders Gülfe has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 5 papers in Economics and Econometrics and 4 papers in Surgery. Recurrent topics in Anders Gülfe's work include Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Lupus Erythematosus Research (7 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Anders Gülfe is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Lupus Erythematosus Research (7 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Anders Gülfe collaborates with scholars based in Sweden, Denmark and Austria. Anders Gülfe's co-authors include Tore Saxne, Meliha C Kapetanovic, Pierre Geborek, P. Geborek, L. Jacobsson, Ingemar F. Petersson, Lars Erik Kristensen, Carl Turesson, L. E. Kristensen and J. Karlsson and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

Anders Gülfe

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anders Gülfe Sweden	13	829	387	283	116	103	21	1.1k
M Bala United States	8	581 0.7×	479 1.2×	228 0.8×	76 0.7×	134 1.3×	28	1.1k
Piotr Leszczyński Poland	20	914 1.1×	813 2.1×	269 1.0×	108 0.9×	121 1.2×	70	1.5k
Chuanbo Zang United States	11	589 0.7×	386 1.0×	299 1.1×	146 1.3×	112 1.1×	42	1.3k
Gunnstein Bakland Norway	16	909 1.1×	414 1.1×	266 0.9×	60 0.5×	75 0.7×	60	1.1k
Peter Tsao United States	11	798 1.0×	215 0.6×	159 0.6×	86 0.7×	118 1.1×	12	1.1k
Sofia Ernestam Sweden	22	1.2k 1.5×	326 0.8×	452 1.6×	319 2.8×	219 2.1×	44	1.6k
S. Radominski Brazil	16	496 0.6×	251 0.6×	174 0.6×	97 0.8×	226 2.2×	54	970
Sergio Schwartzman United States	21	955 1.2×	548 1.4×	398 1.4×	127 1.1×	163 1.6×	59	1.4k
Farideh Alasti Austria	18	967 1.2×	421 1.1×	354 1.3×	105 0.9×	105 1.0×	41	1.2k
Beverley Harrison United Kingdom	20	1.5k 1.8×	397 1.0×	479 1.7×	157 1.4×	248 2.4×	29	1.9k

Countries citing papers authored by Anders Gülfe

Since Specialization

Citations

This map shows the geographic impact of Anders Gülfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Gülfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Gülfe more than expected).

Fields of papers citing papers by Anders Gülfe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Gülfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Gülfe. The network helps show where Anders Gülfe may publish in the future.

Co-authorship network of co-authors of Anders Gülfe

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Gülfe. A scholar is included among the top collaborators of Anders Gülfe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Gülfe. Anders Gülfe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gülfe, Anders, et al.. (2020). Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties. BMC Musculoskeletal Disorders. 21(1). 410–410. 9 indexed citations

Olofsson, Tor, et al.. (2018). Patient‐Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics‐Treated Patients With Rheumatoid Arthritis. Arthritis Care & Research. 70(11). 1712–1716. 12 indexed citations

Gülfe, Anders, Johan K. Wallman, & Lars Erik Kristensen. (2016). EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Research & Therapy. 18(1). 51–51. 4 indexed citations

Cooper, Annie, Johan K. Wallman, & Anders Gülfe. (2016). What PASSes for good? Experience-based Swedish and hypothetical British EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable symptom state cut-off values in chronic arthritis patients on TNF blockade. Scandinavian Journal of Rheumatology. 45(6). 470–473. 9 indexed citations

Gülfe, Anders, et al.. (2014). Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden. Scandinavian Journal of Rheumatology. 43(6). 493–497. 15 indexed citations

Gülfe, Anders & Adam Linder. (2014). AB0945 Heparin-Binding Protein (HBP) in Joint Fluid Distinguishes Rheumatoid Arthritis from Osteoarthritis. Annals of the Rheumatic Diseases. 73. 1112–1113.

Geborek, Pierre, et al.. (2013). Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthopaedica. 84(5). 495–501. 35 indexed citations

Kristensen, Lars Erik, Henning Bliddal, Robin Christensen, et al.. (2013). Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort. Arthritis Care & Research. 66(2). 173–179. 35 indexed citations

Sandqvist, Gunnel, et al.. (2012). Individualized outcome measures of daily activities are sensitive tools for evaluating hand surgery in rheumatic diseases. Lara D. Veeken. 51(12). 2246–2251. 6 indexed citations

10.

Karlsson, J., Jan Nilsson, Martin Neovius, et al.. (2011). National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 70(12). 2163–2166. 40 indexed citations

11.

Gülfe, Anders, Lars Erik Kristensen, Tore Saxne, et al.. (2010). Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care & Research. 62(10). 1399–1406. 17 indexed citations

12.

Gülfe, Anders, Daniel Aletaha, Tore Saxne, & Pierre Geborek. (2009). Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskeletal Disorders. 10(1). 41–41. 34 indexed citations

13.

Gülfe, Anders, L. E. Kristensen, Tore Saxne, et al.. (2009). Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Annals of the Rheumatic Diseases. 69(2). 352–357. 36 indexed citations

14.

Gülfe, Anders, Lars Erik Kristensen, & Pierre Geborek. (2009). Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden. The Journal of Rheumatology. 36(3). 517–521. 18 indexed citations

15.

Karlsson, J., Lars Erik Kristensen, Meliha C Kapetanovic, et al.. (2007). Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Lara D. Veeken. 47(4). 507–513. 123 indexed citations

16.

Kristensen, L. E., Meliha C Kapetanovic, Anders Gülfe, et al.. (2007). Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Lara D. Veeken. 47(4). 495–499. 131 indexed citations

17.

Kristensen, Lars Erik, Anders Gülfe, Tore Saxne, & P. Geborek. (2007). Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Annals of the Rheumatic Diseases. 67(3). 364–369. 133 indexed citations

18.

Jacobsson, L., Carl Turesson, Anders Gülfe, et al.. (2005). No increase of severe infections in RA patients treated with TNF-blockers. Annals of the Rheumatic Diseases. 64. 461–462. 3 indexed citations

19.

Gülfe, Anders, et al.. (2005). Response criteria for rheumatoid arthritis in clinical practice: how useful are they?. Annals of the Rheumatic Diseases. 64(8). 1186–1189. 29 indexed citations

20.

Gülfe, Anders & Gunnar Sturfelt. (1997). [Severe adverse effect of methotrexate in rheumatoid arthritis. Don't forget security routines in intercurrent disease!].. PubMed. 94(19). 1811–2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact